Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia

NCT04382053 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

143

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19 Pneumonia, Impaired Respiratory Function

Interventions

DRUG: DFV890
DRUG: Standard of Care (SoC)

Sponsor

Novartis Pharmaceuticals